Understanding how mitochondrial DNA damage affects Parkinson's disease
Mechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's disease
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11054722
This study is looking at how damage to the tiny powerhouses in our cells, called mitochondria, might play a role in Parkinson's disease, especially for those with a specific gene mutation, and it hopes to find new ways to help improve treatment for people living with this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11054722 on ClinicalTrials.gov |
What this research studies
This research investigates the role of mitochondrial DNA damage in both familial and idiopathic Parkinson's disease (PD). It focuses on how mutations in the LRRK2 gene contribute to mitochondrial dysfunction, which is a common feature in PD. The study aims to explore the mechanisms by which ATM, a protein involved in DNA damage repair, is activated in response to mitochondrial DNA damage and how this process may influence the progression of PD. By examining these molecular pathways, the research seeks to identify potential therapeutic targets to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with familial or idiopathic Parkinson's disease, particularly those over 21 years old.
Not a fit: Patients with Parkinson's disease who do not have mitochondrial dysfunction or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that not only alleviate symptoms of Parkinson's disease but also slow its progression.
How similar studies have performed: Preliminary studies have shown promise in similar approaches, indicating that targeting the ATM-mediated DNA damage response may be a viable strategy for addressing mitochondrial dysfunction in Parkinson's disease.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SANDERS, LAURIE H — DUKE UNIVERSITY
- Study coordinator: SANDERS, LAURIE H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.